Pregabalin Sandoz 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
N/0034 
Minor change in labelling or package leaflet not 
16/11/2023 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0033 
A.5.b - Administrative change - Change in the name 
21/09/2023 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
(excluding manufacturer for batch release) 
IB/0031 
B.II.f.1.d - Stability of FP - Change in storage 
13/06/2023 
conditions of the finished product or the 
diluted/reconstituted product 
SmPC, 
Labelling and 
PL 
IA/0032 
B.III.1.a.2 - Submission of a new/updated or 
05/06/2023 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0030 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/01/2023 
15/02/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0028 
C.I.2.a - Change in the SPC, Labelling or PL of a 
21/11/2022 
15/02/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0029 
C.I.11.z - Introduction of, or change(s) to, the 
16/11/2022 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0027/G 
This was an application for a group of variations. 
05/09/2022 
n/a 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.4 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Deletion of certificates (in case multiple certificates 
exist per material) 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
Page 3/11 
 
 
 
 
 
B.III.1.b.3 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
Updated certificate from an already approved 
manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
B.III.1.b.2 - Submission of a new/updated or 
deletion of Ph. Eur. TSE Certificate of Suitability - 
New certificate for a starting 
material/reagent/intermediate/or excipient from a 
new or an already approved manufacturer 
IB/0026 
C.I.2.a - Change in the SPC, Labelling or PL of a 
30/06/2022 
15/02/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 4/11 
 
 
 
 
 
 
 
IAIN/0025 
C.I.z - Changes (Safety/Efficacy) of Human and 
19/04/2022 
15/02/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0023 
C.I.2.a - Change in the SPC, Labelling or PL of a 
23/02/2022 
15/02/2023 
SmPC and PL 
To update Section 4.8 of the SmPC and section 4 of 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Package Leaflet  following assessment of the same changes 
adopted for the parent product Lyrica, to which safety 
changes were adopted per 
EMEA/H/C/PSUSA/00002511/202101.   
The MAH took the opportunity to implement minor editorial 
changes and allignement to the QRD 10.1. 
IA/0024 
B.II.e.6.b - Change in any part of the (primary) 
26/01/2022 
n/a 
packaging material not in contact with the finished 
product formulation - Change that does not affect 
the product information 
IB/0022 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/12/2021 
16/02/2022 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IB/0020/G 
This was an application for a group of variations. 
03/12/2021 
16/02/2022 
Annex II and 
PL 
B.II.e.1.z - Change in immediate packaging of the 
finished product - Other variation 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.b.1.a - Replacement or addition of a 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
IAIN/0019 
B.II.e.5.a.1 - Change in pack size of the finished 
07/07/2021 
16/02/2022 
SmPC, 
To add a new pack size of 100x1 hard capsules (no 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Labelling and 
multipack) for Pregabalin Sandoz 300mg 
PL 
IA/0018 
A.5.b - Administrative change - Change in the name 
15/06/2021 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0017 
To add a new pack-size of 100 hard capsules in 
02/06/2021 
16/02/2022 
SmPC, 
blister (PVC/PVDC/alu) for Pregabalin Sandoz 300mg 
(EU/1/15/1011/086). 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
the range of the currently approved pack sizes 
IB/0016 
B.II.a.3.z - Changes in the composition (excipients) 
12/05/2021 
n/a 
of the finished product - Other variation 
IB/0015/G 
This was an application for a group of variations. 
26/01/2021 
16/02/2022 
SmPC, 
Labelling and 
PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0014 
B.III.1.a.2 - Submission of a new/updated or 
10/07/2020 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
R/0012 
Renewal of the marketing authorisation. 
30/04/2020 
19/06/2020 
SmPC and PL 
Based on the review of data on quality, safety and efficacy, 
the CHMP considered that the benefit-risk balance of 
Pregabalin Sandoz in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0013/G 
This was an application for a group of variations. 
09/12/2019 
n/a 
B.I.b.1.c - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IB/0011 
B.II.d.1.a - Change in the specification parameters 
30/04/2019 
n/a 
and/or limits of the finished product - Tightening of 
specification limits 
IAIN/0010 
B.III.1.a.3 - Submission of a new/updated or 
23/10/2018 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from a 
new manufacturer (replacement or addition) 
IB/0009/G 
This was an application for a group of variations. 
26/01/2018 
07/01/2019 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0008 
A.5.b - Administrative change - Change in the name 
07/12/2017 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
IAIN/0007/G 
This was an application for a group of variations. 
27/10/2017 
n/a 
A.5.a - Administrative change - Change in the name 
and/or address of a manufacturer/importer 
responsible for batch release 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.1.a.1 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
B.III.2.a.1 - Change of specification(s) of a former 
non EU Pharmacopoeial substance to fully comply 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
 
with the Ph. Eur. or with a national pharmacopoeia of 
a Member State - AS 
IB/0005 
C.I.2.a - Change in the SPC, Labelling or PL of a 
06/03/2017 
05/02/2018 
SmPC, Annex 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
II, Labelling 
and PL 
IA/0004/G 
This was an application for a group of variations. 
04/12/2015 
n/a 
B.II.b.4.a - Change in the batch size (including batch 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
B.II.e.1.a.1 - Change in immediate packaging of the 
finished product - Qualitative and quantitative 
composition - Solid pharmaceutical forms 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
IB/0003 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
15/10/2015 
06/10/2016 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0001/G 
This was an application for a group of variations. 
02/10/2015 
06/10/2016 
SmPC, 
B.II.e.5.a.2 - Change in pack size of the finished 
Labelling and 
PL 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
B.II.e.5.a.2 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
IB/0002/G 
This was an application for a group of variations. 
24/09/2015 
n/a 
B.I.b.2.e - Change in test procedure for AS or 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
 
